VHT - Vanguard Health Care ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
170.4500
-1.5200 (-0.88%)
As of 2:10PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close171.9700
Open171.9700
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range169.9100 - 172.3500
52 Week Range148.3100 - 181.9200
Volume129,646
Avg. Volume235,796
Net Assets10.28B
NAV180.37
PE Ratio (TTM)70.58
Yield1.20%
YTD Return18.17%
Beta (3Y Monthly)0.96
Expense Ratio (net)0.10%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • Top-Ranked Healthcare ETFs for Long-Term Investors
    Zacks4 days ago

    Top-Ranked Healthcare ETFs for Long-Term Investors

    Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.

  • ETF Trends12 days ago

    Health Care ETFs Retreat on DOJ Approval of Aetna-CVS Merger

    The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.

  • Zacks18 days ago

    Dow Closes at Another New High

    Dow Closes at Another New High

  • Investopedia19 days ago

    Why Stock Market's 'Out of Whack' Leadership Signals Next Crash

    Defensive stocks are market leaders, and that signals big trouble ahead, per Jim Paulsen of The Leuthold Group.

  • New Innovation Spurring a Biotech Rejuvenation
    Harvest Exchange27 days ago

    New Innovation Spurring a Biotech Rejuvenation

    Author Evan McCulloch Senior Vice President, Director of Research Franklin Equity Group® Portfolio Manager, Franklin Biotechnology Discovery Fund Since hitting an all-time high in July 2015, biotech stocks, as measured by the NASDAQ Biotechnology ...

  • Investor's Business Dailylast month

    Online Retail, Small-Cap Stocks Among Market Pro's Top Picks

    Internet retail, small-cap and a health care stock fund are among SFMG Wealth Advisor's top ETF picks for the coming months.

  • Investopedialast month

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in the first eight months of 2018 has created investment opportunities. These ETFs are poised to take advantage.

  • Investopedia2 months ago

    3 ETFs for Johnson & Johnson's Healthy Breakout

    Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, has underperformed the broader market in 2018. The company's stock is down 3.66% year to date (YTD), while the Standard and Poor's 500 index (S&P 500) is up roughly 7%. David Katz, chief investment officer at Matrix Asset Advisors, told Reuters, "We are much more upbeat about Johnson & Johnson today than we were six months ago.

  • ETF Trends2 months ago

    7 Healthcare ETFs Among Best Performing Defensive Picks This Year

    The healthcare sector and related ETFs have been among the best performing defensive plays this year as strong earnings and potential Trump administration actions on drug pricing drew greater investment ...

  • ETF Trends2 months ago

    Investors Flock to This Vanguard Sector ETF

    The healthcare sector is one of this year's best-performing sectors and the group's recent strength is luring some investors to the related exchange traded funds. For healthcare ETFs, the good news is that the U.S. economy moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up. “The $8.2 billion Vanguard Health Care ETF, known by its ticker VHT, had 1.6 million shares worth $272 million trade Monday, record one-day turnover for the fund.

  • ETF Trends2 months ago

    Investors Flocked to Healthcare ETFs in July

    With the healthcare sector recently outperforming technology, investors have been embracing healthcare exchange traded funds. The Health Care Select Sector SPDR (XLV) is the largest healthcare ETF by assets. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.

  • 5 ETFs for a Historically Low August
    InvestorPlace3 months ago

    5 ETFs for a Historically Low August

    The month of August started off on a shaky note for Wall Street with Fed imposed rising rate concerns and severity in the U.S.-Sino trade relations coming to the forefront.The Trump administration is reportedly considering a hike in tariffs from 10% to 20% on $200 billion worth of Chinese goods, after a 25% tariff announcement on $50 billion worth of goods.Source: Shutterstock

  • 5 ETFs for a Historically Low August
    Zacks3 months ago

    5 ETFs for a Historically Low August

    Trade war talks and faster Fed rate hike concerns may mess with Wall Street in August. These five picks may save investors.

  • Investopedia3 months ago

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.

  • Business Wire4 months ago

    E*TRADE Adds Several of Today’s Most Popular ETFs to Commission-Free ETF Lineup

    E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr

  • 3 Top Index Funds to Keep You in the Investing Game
    Motley Fool5 months ago

    3 Top Index Funds to Keep You in the Investing Game

    A few great places to park your cash when you'd rather not direct it toward a single stock.

  • A Overview of Merck’s Diabetes Products in 1Q18
    Market Realist5 months ago

    A Overview of Merck’s Diabetes Products in 1Q18

    Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.

  • Allergan’s US General Medicines Segment in 1Q18
    Market Realist6 months ago

    Allergan’s US General Medicines Segment in 1Q18

    Allergan’s (AGN) US General Medicines segment includes revenues from the US sales of its central nervous system products, women’s health products, gastrointestinal products, anti-infective products, and diversified brands.

  • Mounting Evidence of Inflation Firming Up
    Market Realist6 months ago

    Mounting Evidence of Inflation Firming Up

    The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index4 jumped to a 14-year high and the Conference Board Consumer Confidence Index5 hovers near 17-year highs. This suggests that while times are good for most people, they have little desire to spend more in an economic expansion that is one of the longest on record. Households may save their gains from the Trump tax cuts, rather than spend in the economy, as the Commerce Department reports the savings rate ticked higher in February.

  • Merck’s 1Q18 Estimates: Revenues Expected to Increase
    Market Realist6 months ago

    Merck’s 1Q18 Estimates: Revenues Expected to Increase

    Analysts expect Merck & Co.’s (MRK) revenues to increase ~7.1% to $10.1 billion in 1Q18, compared to revenues of $9.4 billion in 1Q17. Revenues for 1Q18 are expected to have a positive impact on growth in operating revenues and a favorable impact from foreign exchange.

  • Allergan Reports 1Q18 Earnings, Revenue Growth
    Market Realist6 months ago

    Allergan Reports 1Q18 Earnings, Revenue Growth

    Allergan (AGN) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues today. It reported EPS of $3.74 on revenues of $3.7 billion, compared to EPS of $3.36 on revenues of $3.6 billion in 1Q18.

  • What Analysts Expect for Pfizer in 1Q18
    Market Realist6 months ago

    What Analysts Expect for Pfizer in 1Q18

    Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer (PFE) is set to release its 1Q18 earnings on May 1, 2018. Wall Street analysts estimate Pfizer will report earnings per share (or EPS) of $0.74 on revenues of $13.1 billion for 1Q18.

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist6 months ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • InvestorPlace7 months ago

    The 3 Best Low-Cost Retirement Funds

    When it comes to assessing the cost of a retirement mutual fund or exchange-traded fund, most investors simply look at the absolute value of the expense ratio. The lower the expense ratio, they figure, the better. For some ETFs and funds, the definition of low-cost retirement funds is relative.

  • Analysts’ Recommendations for Johnson & Johnson in March 2018
    Market Realist7 months ago

    Analysts’ Recommendations for Johnson & Johnson in March 2018

    Analyzing Johnson & Johnson’s Stock and Valuations in March 2018